Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 520-523, 2006; 10.1373/clinchem.2005.062844
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplements
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xi, L.
Right arrow Articles by Hughes, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xi, L.
Right arrow Articles by Hughes, S. J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2006;52:520-523.)
© 2006 American Association for Clinical Chemistry, Inc.

Technical Briefs

Identification of mRNA Markers for Molecular Staging of Lymph Nodes in Colorectal Cancer

Liqiang Xi1,1, William Gooding2, Kenneth McCarty3, Tony E. Godfrey1 and Steven J. Hughes1,a

Departments of1 Surgery and3 Pathology, and the 2 Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA;

aaddress correspondence to this author at: University of Pittsburgh, 497 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261; fax 412-648-2045, e-mail Hughess2{at}upmc.edu


Abstract

Background: One evolving approach to improved prognostication of cancer patients is the identification of previously occult disease by use of quantitative reverse transcription-PCR. Surprisingly, no systematic analysis of potential mRNA markers for colorectal cancer has been reported. We therefore performed an extensive mRNA marker survey for colorectal cancers.

Methods: We identified potential markers through literature and database searches. We analyzed all markers by quantitative reverse transcription-PCR on a limited set of primary tumors and benign lymph nodes. Selected markers were further evaluated on a larger tissue set with positive lymph nodes.

Results: We evaluated 43 markers and undertook further analysis of 6 in the secondary screening. Five gene markers—CDX1, carcinoembryonic antigen (CEA), CK20, TACSTD1, and Villin1 (VIL1)—provided perfect classification of lymph node status.

Conclusions: Several mRNA markers are capable of providing exceptionally accurate characterization of lymph node status in colorectal cancer. An automated, multimarker, quantitative reverse transcription-PCR assay for characterization of lymph nodes from colorectal cancer patients may be useful for improved staging and therapeutic decision making in colorectal cancer.




The following articles in journals at HighWire Press have cited this article:


Home page
 Ann OncolHome page
S. Benlloch, J. M. Galbis-Caravajal, C. Alenda, F. M. Peiro, M. Sanchez-Ronco, J. M. Rodriguez-Paniagua, B. Baschwitz, E. Rojas, and B. Massuti
Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases
Ann. Onc., January 1, 2009; 20(1): 91 - 97.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
D. G. Nicastri, J. T. Doucette, T. E. Godfrey, and S. J. Hughes
Is Occult Lymph Node Disease in Colorectal Cancer Patients Clinically Significant?: A Review of the Relevant Literature
J. Mol. Diagn., November 1, 2007; 9(5): 563 - 571.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.